Last $1.14 USD
Change Today -0.035 / -2.99%
Volume 289.4K
ETRM On Other Exchanges
As of 1:42 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

enteromedics inc (ETRM) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/14 - $2.65
52 Week Low
10/13/14 - $0.99
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ENTEROMEDICS INC (ETRM)

enteromedics inc (ETRM) Related Businessweek News

No Related Businessweek News Found

enteromedics inc (ETRM) Details

EnteroMedics Inc., a development stage medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. It develops the Maestro System, which limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. The company is evaluating the Maestro System in human clinical trials in the United States, Australia, Mexico, and Norway. EnteroMedics Inc. has collaboration with Mayo Clinic for the development and testing of products for the treatment of obesity. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003. EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.

27 Employees
Last Reported Date: 03/27/14
Founded in 2002

enteromedics inc (ETRM) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $354.0K
Co-Founder and Vice President of Clinical & R...
Total Annual Compensation: $264.3K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $293.2K
Senior Vice President of Research & Advanced ...
Total Annual Compensation: $263.7K
Compensation as of Fiscal Year 2013.

enteromedics inc (ETRM) Key Developments

FDA Approves EnteroMedics Inc.'s First Medical Device for Obesity Treatment Targeting Brain-To-Stomach Signaling

The United States Food and Drug Administration (FDA) approved EnteroMedic's VBLOC® vagal blocking therapy, delivered via the Maestro® System, which is the first medical device approved for obesity treatment that targets the nerve pathway between the brain and the stomach. The device acts by sending an electrical pulse to block vagal nerve signals involved in controlling feelings of hunger and fullness. The Maestro System is approved for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 35 to 45 kg/m2 with one or more obesity-related health condition and who have failed to lose weight in a supervised weight management program within the past five years. This is a novel device that interrupts signals from the stomach to the brain that are believed to be involved with stomach emptying and feelings of fullness. In clinical trials the device resulted in a clinically meaningful weight loss of 8.5% after one year and the FDA determined this was an appropriate risk-benefit profile to approve the device for clinical use. The FDA has requested the company collect additional safety and efficacy over five years.

EnteroMedics Inc. - Special Call

To discuss FDA Approval of VBLOC Vagal Blocking Therapy for the Treatment of Obesity

EnteroMedics Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

EnteroMedics Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported operating loss of $5,594,000 against $5,970,000 a year ago. Net loss was $5,714,000 or $0.08 per basic and diluted share against $6,303,000 or $0.11 per basic and diluted share a year ago. For the nine months, the company reported operating loss of $9,506,000 against $18,360,000 a year ago. Net loss was $19,948,000 or $0.30 per basic and diluted share against $19,207,000 or $0.36 per basic and diluted share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ETRM:US $1.14 USD -0.035

ETRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ETRM.
View Industry Companies

Industry Analysis


Industry Average

Valuation ETRM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENTEROMEDICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at